title: The influence of herbal medicine ursolic acid on the uptake of rosuvastatin mediated by OATP1B1*1a and *5.
abstract: Chinese herbal medicines such as hawthorn, salvia, etc., are frequently combined with statins so as to treat cardiovascular diseases more effectively. Chinese herbal medicines contain many kinds of active components, which may have drug-drug interactions with statins. This study aims to explore the effect and mechanism by which ursolic acid affects OATP1B1-mediated transport of rosuvastatin. This study will explore the effect of ursolic acid on OAPT1B1-mediated transport of rosuvastatin in the different cell systems. Given the genetic polymorphisms of OATP1B1, simultaneously, this study will further explore the effect of ursolic acid on OATP1B1 (521T>C)-mediated transport of rosuvastatin. When the concentration of ursolic acid was 1.8 and 18 µM, it showed that ursolic acid significantly inhibits the uptake of rosuvastatin in both OATP1B1*1a-HEK 293T cells and OATP1B1*5-HEK 293T cells. The reduction of OATP1B1*1a transport of rosuvastatin were 34.60 ± 2.99 and 66.08 ± 1.83 %, and for OATP1B1*5 were 34.27 ± 7.08 % and 66.95 ± 1.14 %. Inhibitory parameters of IC50 were 6.25 ± 0.42 and 6.07 ± 0.57 µM, respectively. This study suggests that ursolic acid can affect the uptake of rosuvastatin in hepatocytes by inhibiting the transport of OATP1B1, and gene mutation of OATP1B1 may cause different effects on its transport of rosuvastatin.
authors.affiliation: Department of Pharmacy, The First Affiliated Hospital of Nanchang University, Nanchang, China, wenjh866@163.com.
authors.forename: Wen Jin
authors.initials: WJ
authors.lastname: Hua
authors.forename: Wei Xiao
authors.initials: WX
authors.lastname: Hua
authors.forename: Fu Yong
authors.initials: FY
authors.lastname: Nan
authors.forename: Wang An
authors.initials: WA
authors.lastname: Jiang
authors.forename: Chen
authors.initials: C
authors.lastname: Yan
mesh_terms: D000818:Animals; D001692:Biological Transport; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D005838:Genotype; D057809:HEK293 Cells; D022781:Hepatocytes / Q000187:drug effects* / Q000378:metabolism*; D041743:Herb-Drug Interactions; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D027361:Organic Anion Transporters / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism*; D010641:Phenotype; D011110:Polymorphism, Genetic; D051381:Rats; D000068718:Rosuvastatin Calcium / Q000378:metabolism*; D014315:Triterpenes / Q000494:pharmacology*; D000097245:Ursolic Acid
chemical_list: D004365:Drugs, Chinese Herbal; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D027361:Organic Anion Transporters; D000068718:Rosuvastatin Calcium; D014315:Triterpenes; D000097245:Ursolic Acid; C503597:Slco1a4 protein, rat
references.citation: Expert Opin Drug Saf. 2011 Nov;10(6):969-86
references.pmid: 21999163
references.citation: Annu Rev Pharmacol Toxicol. 2012;52:135-51
references.pmid: 21854228
references.citation: Clin Pharmacol Ther. 1999 Mar;65(3):251-61
references.pmid: 10096257
references.citation: Br J Pharmacol. 2009 Oct;158(3):693-705
references.pmid: 19785645
references.citation: Bioorg Med Chem Lett. 2011 Oct 1;21(19):5876-80
references.pmid: 21855333
references.citation: Clin Chim Acta. 2006 Nov;373(1-2):99-103
references.pmid: 16784736
references.citation: Curr Chem Genomics. 2010 Mar 01;4:1-8
references.pmid: 20448812
references.citation: Life Sci. 2004 Apr 16;74(22):2769-79
references.pmid: 15043991
references.citation: Cardiovasc Ther. 2012 Oct;30(5):e234-41
references.pmid: 21884024
references.citation: Methods Cell Biol. 1976;13:29-83
references.pmid: 177845
references.citation: Drug Metab Dispos. 2008 Oct;36(10):2014-23
references.pmid: 18617601
references.citation: Eur J Drug Metab Pharmacokinet. 2011 Dec;36(4):205-11
references.pmid: 21717139
references.citation: Pharmacogenet Genomics. 2005 Jul;15(7):513-22
references.pmid: 15970799
references.citation: Anal Biochem. 1976 May 7;72:248-54
references.pmid: 942051
references.citation: Xenobiotica. 2011 Jan;41(1):24-34
references.pmid: 20946088
references.citation: Yao Xue Xue Bao. 2011 Jun;46(6):695-700
references.pmid: 21882531
references.citation: Clin Pharmacol Ther. 2008 Feb;83(2):251-7
references.pmid: 17568401
references.citation: Pharmacol Rev. 2003 Sep;55(3):425-61
references.pmid: 12869659
references.citation: Toxicol In Vitro. 2010 Mar;24(2):605-10
references.pmid: 19853032
references.citation: Drug Metab Dispos. 2007 May;35(5):779-86
references.pmid: 17296622
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Jan 15;879(2):219-24
references.pmid: 21169069
references.citation: Pharmacogenomics. 2007 Jul;8(7):787-802
references.pmid: 18240907
references.citation: J Pharmacol Exp Ther. 2002 Aug;302(2):804-13
references.pmid: 12130747
references.citation: J Biol Chem. 2001 Sep 21;276(38):35669-75
references.pmid: 11477075
references.citation: Drug Metab Pharmacokinet. 2012;27(1):106-21
references.pmid: 22185815
references.citation: J Biol Chem. 1999 Jun 11;274(24):17159-63
references.pmid: 10358072
references.citation: Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):363-79
references.pmid: 18433342
references.citation: J Pharmacol Exp Ther. 2003 Feb;304(2):610-6
references.pmid: 12538813
references.citation: Curr Opin Investig Drugs. 2010 Mar;11(3):323-32
references.pmid: 20178046
references.citation: Curr Drug Metab. 2011 Nov;12(9):835-49
references.pmid: 21619518
references.citation: Evid Based Complement Alternat Med. 2012;2012:967182
references.pmid: 22988478